乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ACC

<乌鸦传媒>SURTAVI: TAVR Matches Surgery in Lowest-Risk Cohort

But reinterventions, parvalvular regurgitation, and pacemaker implants mar a supposed victory

<乌鸦传媒>FOURIER Opens ACC With a Bang

Big LDL reduction, prevents MI, but with big price tag

<乌鸦传媒>Study: Erectile Dysfunction Drugs Safe After MI

Outcomes actually better among users in Swedish database

<乌鸦传媒>ACC: Looking Beyond Statins in LDL Lowering

New ACC guidance maps a path

<乌鸦传媒>ACC: Placebo Challenge for Statin Intolerance?

Cardiologists debate whether strategy might work in the clinic too

<乌鸦传媒>ACC: No Benefit for Beta-Blocker Before PCI

IV metoprolol was safe, but disappointing

<乌鸦传媒>CNN Calls Out 'Cataract Risk' in HOPE-3

Statins and cataracts: So what?

<乌鸦传媒>ACC: After a Decade, CABG Pulls Ahead of Meds for HF

Life-saving benefit of CABG now clear in long-term trial follow-up

<乌鸦传媒>Entresto: Why Is There Silence? We're Not Selling iPhones

The drug hailed as a true PARADIGM shift, is slow out of the gate

<乌鸦传媒>ACC: Evolocumab May Be Best Option for Statin Intolerance

Far greater LDL reduction but still some muscle complaints in GAUSS-3 trial

<乌鸦传媒>ACC: TAVR Once Again Non-Inferior to Surgery

No excess stroke or mortality at 2 years in lowest risk trial population yet studied

<乌鸦传媒>ACC: HOPE Results Boost Statin Prevention Role

Mortality and nonfatal events reduced

<乌鸦传媒>ACC: Folate Supplements Cut Strokes in Hypertension

Hypertensive patients with low blood folate levels gain big benefit.

<乌鸦传媒>ACC: Metformin No Help in MI Recovery

WASHINGTON -- Metformin started soon after reperfusion in the acute setting didn't help cardiac function recover in nondiabetic heart attack patients, a trial showed.

<乌鸦传媒>ACC: Gout Drug Tames the Heart

WASHINGTON -- Colchicine may be as effective at reducing multiple recurrences of pericarditis as it is in treating acute episodes and first recurrences.

<乌鸦传媒>ACC: Still No Clear CHOICE for TAVI

WASHINGTON -- Head-to-head comparison of transcatheter aortic valve implantation (TAVI) devices favored the second-generation Sapien XT over CoreValve, although the trial was criticized on several fronts.

<乌鸦传媒>ACC: CoreValve Bests Surgery

WASHINGTON -- Transcatheter aortic valve implantation (TAVI) with the CoreValve device improved survival compared with surgery in the high-risk pivotal trial cohort.

<乌鸦传媒>ACC: Statins Tied to Boost in Men's Sexual Function

WASHINGTON -- Statins appeared to improve erectile function to a clinically meaningful degree, according to a meta-analysis.

<乌鸦传媒>ACC: Is Chelation Plus Vitamins a Winning Combo?

SAN FRANCISCO -- Vitamins alone won't improve outcomes for patients who've had a heart attack, but they do appear to have additive benefits when given in conjunction with controversial chelation therapy, researchers reported here.

<乌鸦传媒>ACC: Triglycerides Decreased with Rosuvastatin Therapy

ATLANTA -- In a study that specifically scrutinized the effects of statin therapy on triglycerides, researchers said that rosuvastatin (Crestor) significantly reduced the blood lipid that has been linked to coronary artery disease better than placebo.

<乌鸦传媒>ACC: Clopidogrel Black Box Likely to Have Immediate Clinical Impact

ATLANTA -- The FDA's decision to add a black box warning to the label of clopidogrel (Plavix) came without warning to doctors attending the American College of Cardiology meeting here. But getting the word out to more than 13,000 cardiologists gathered in this city not an easy task.

<乌鸦传媒>ACC: FDA Announces Review of ACCORD Data

ATLANTA -- The FDA said it will conduct a full review of findings from a study which concluded that neither aggressive lipid-lowering therapy nor tight blood pressure control reduced cardiovascular events in persons with diabetes.

<乌鸦传媒>ACC: Senate Probe Finds Evidence that Drug Firms Worked to Delay ENHANCE Results

CHICAGO -- E-mails made public today described outrage more than a year ago by the ENHANCE trial's principal investigator because he perceived that a drugmaker was withholding bad results about ezetimibe/simvastatin (Vytorin) for non-scientific reasons.

<乌鸦传媒>ACC: Coronary Artery Disease Patients Should Have Low LDL Goal

ATLANTA, March 10 - For all patients with stable coronary artery disease (CAD), the goal of therapy should be to get LDL cholesterol lower than 70 mg/dL, said Christie Ballantyne, M.D., director of the center for cardiovascular disease prevention at Baylor College of Medicine in Houston.